Search Results
Search for other papers by Trevor M Penning in
Google Scholar
PubMed
emerged in the tumor. This form of the disease is known as castration-resistant prostate cancer (CRPC), which is almost uniformly fatal. The adaptive androgen signaling in CRPC cells can occur due to intratumoral androgen biosynthesis and/or changes in the
Department of Urology, People’s Hospital of Longhua, Shenzhen, China
Search for other papers by Zhu Wang in
Google Scholar
PubMed
The Clinical Innovation & Research Center, Shenzhen Hospital, Southern Medical University, Shenzhen, China
Search for other papers by Dinglan Wu in
Google Scholar
PubMed
Search for other papers by Chi-Fai Ng in
Google Scholar
PubMed
Search for other papers by Jeremy Yuen-Chun Teoh in
Google Scholar
PubMed
Search for other papers by Shan Yu in
Google Scholar
PubMed
Search for other papers by Yuliang Wang in
Google Scholar
PubMed
Search for other papers by Franky L Chan in
Google Scholar
PubMed
antagonist-to-agonist switch due to AR mutation and intra-tumoral androgen biosynthesis, are critically involved in its advanced progression to androgen-insensitive and metastatic stages (castration-resistant or hormone-refractory prostate cancer CRPC) and
Search for other papers by Ying Ying Sung in
Google Scholar
PubMed
Search for other papers by Edwin Cheung in
Google Scholar
PubMed
AstraZeneca, London, UK) has been utilized as standard treatments for patients with advanced prostate cancers. Despite initial good responses, tumors invariably recur and develop into a lethal form of the disease, known as castration-resistant prostate cancer
Department of Medical Oncology, University of Sydney, Cancer Research Program, Sydney Cancer Centre, Missenden Road, Camperdown, New South Wales 2050, Australia
Department of Medical Oncology, University of Sydney, Cancer Research Program, Sydney Cancer Centre, Missenden Road, Camperdown, New South Wales 2050, Australia
Search for other papers by Kate L Mahon in
Google Scholar
PubMed
Search for other papers by Susan M Henshall in
Google Scholar
PubMed
Search for other papers by Robert L Sutherland in
Google Scholar
PubMed
Department of Medical Oncology, University of Sydney, Cancer Research Program, Sydney Cancer Centre, Missenden Road, Camperdown, New South Wales 2050, Australia
Department of Medical Oncology, University of Sydney, Cancer Research Program, Sydney Cancer Centre, Missenden Road, Camperdown, New South Wales 2050, Australia
Search for other papers by Lisa G Horvath in
Google Scholar
PubMed
cancer initially responds to anti-androgen therapy; however, it eventually becomes resistant to hormonal manipulation. Chemotherapy remains the only treatment option in the setting of castration-resistant prostate cancer (CRPC) providing modest survival
Search for other papers by Rhonda L Bitting in
Google Scholar
PubMed
Search for other papers by Andrew J Armstrong in
Google Scholar
PubMed
chemical or surgical castration is the first-line therapy for metastatic disease. Response to therapy, however, is temporary, and patients invariably progress to castration-resistant prostate cancer (CRPC; Rini & Small 2002 ). The TAX327 trial established
Department of Tumor Radiotherapy, 3rd Hospital of PLA, Bao Ji, China
Search for other papers by Peng Ning in
Google Scholar
PubMed
Search for other papers by Jia-guo Zhong in
Google Scholar
PubMed
Search for other papers by Fan Jiang in
Google Scholar
PubMed
Search for other papers by Yi Zhang in
Google Scholar
PubMed
Search for other papers by Jie Zhao in
Google Scholar
PubMed
Search for other papers by Feng Tian in
Google Scholar
PubMed
Search for other papers by Wei Li in
Google Scholar
PubMed
castration-resistant prostate cancer (CRPC) ( Karzai et al . 2015 ). Several chemical agents such as docetaxel, although previously reported to improve overall survival in men with CRPC, fail to prolong the prognosis of CRPC patients by >6months ( Suzman
Search for other papers by Howard I Scher in
Google Scholar
PubMed
Search for other papers by Grant Buchanan in
Google Scholar
PubMed
Search for other papers by William Gerald in
Google Scholar
PubMed
Search for other papers by Lisa M Butler in
Google Scholar
PubMed
Search for other papers by Wayne D Tilley in
Google Scholar
PubMed
prostate cancers after the failure of AAT, and in castrate-resistant CWR22 xenografts ( Anzick et al. 1997 , Gregory et al. 2001 b ). In clinical studies, the concentrations of key AR coregulators, including p300/CBP, have been shown to increase
Freemasons Foundation Centre for Men’s Health, School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia
Search for other papers by Isabel Coutinho in
Google Scholar
PubMed
Freemasons Foundation Centre for Men’s Health, School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia
Search for other papers by Tanya K Day in
Google Scholar
PubMed
Freemasons Foundation Centre for Men’s Health, School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia
Search for other papers by Wayne D Tilley in
Google Scholar
PubMed
Freemasons Foundation Centre for Men’s Health, School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia
Search for other papers by Luke A Selth in
Google Scholar
PubMed
almost all men, development of resistance is inevitable, normally occurring within a period of 2–3 years. The resultant form of the disease, termed as castration-resistant prostate cancer (CRPC), is incurable and lethal ( Scher et al . 2004 , Thoreson
Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada
Search for other papers by Zhi Long in
Google Scholar
PubMed
Search for other papers by Yinan Li in
Google Scholar
PubMed
Department of Urology, Xiangya Hospital, Central South University, Changsha, China
Search for other papers by Yu Gan in
Google Scholar
PubMed
Department of Cardiothoracic Surgeries, Weill Cornell Medical College, Cornell University, New York, New York, USA
Institute for Academic Medicine, Houston Methodist Hospital, Houston, Texas, USA
Search for other papers by Dongyu Zhao in
Google Scholar
PubMed
Department of Cardiothoracic Surgeries, Weill Cornell Medical College, Cornell University, New York, New York, USA
Institute for Academic Medicine, Houston Methodist Hospital, Houston, Texas, USA
Search for other papers by Guangyu Wang in
Google Scholar
PubMed
Search for other papers by Ning Xie in
Google Scholar
PubMed
Search for other papers by Jessica M Lovnicki in
Google Scholar
PubMed
Search for other papers by Ladan Fazli in
Google Scholar
PubMed
Search for other papers by Qi Cao in
Google Scholar
PubMed
Department of Cardiothoracic Surgeries, Weill Cornell Medical College, Cornell University, New York, New York, USA
Institute for Academic Medicine, Houston Methodist Hospital, Houston, Texas, USA
Search for other papers by Kaifu Chen in
Google Scholar
PubMed
Search for other papers by Xuesen Dong in
Google Scholar
PubMed
in fully developed prostate in males, and whether HOXA10 regulates signal pathways during prostate cancer (PCa) development or tumor progression into the castrate-resistant stage. PCa is the most commonly diagnosed cancer in males. The primary
Search for other papers by Masaki Shiota in
Google Scholar
PubMed
Search for other papers by Ario Takeuchi in
Google Scholar
PubMed
Departments of, Urology, Anatomic Pathology, Clinical Chemistry and Laboratory Medicine, Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
Search for other papers by YooHyun Song in
Google Scholar
PubMed
Search for other papers by Akira Yokomizo in
Google Scholar
PubMed
Search for other papers by Eiji Kashiwagi in
Google Scholar
PubMed
Search for other papers by Takeshi Uchiumi in
Google Scholar
PubMed
Search for other papers by Kentaro Kuroiwa in
Google Scholar
PubMed
Search for other papers by Katsunori Tatsugami in
Google Scholar
PubMed
Search for other papers by Naohiro Fujimoto in
Google Scholar
PubMed
Search for other papers by Yoshinao Oda in
Google Scholar
PubMed
Search for other papers by Seiji Naito in
Google Scholar
PubMed
HI Sawyers CL 2005 Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis . Journal of Clinical Oncology 23 8253 – 8261 doi:10.1200/JCO.2005.03.4777 . Sharifi N